Clinical trials: Oncology Pain
Bone Metastasis
Bone Pain Score Validation Initiative
Translation and validation of the BOMET-QoL-10 questionnaire in Germany and assessment of its validity and responsiveness.
- Trial name
- ARIE (NCT02293642)
- Where
- Germany
- Volunteers
- 370 people
- Sponsor
- iOMEDICO AG
Opioid-Induced Constipation
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC) in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01901341
- Testing
- CB-5945
- Volunteers
- 44 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Lung Cancer, Pain
Fentanyl Matrix in Lung Cancer Pain
The purpose of this study is to evaluate the usefulness of fentanyl matrix by assessing patients' satisfaction when administrating fentanyl matrix, a background pain treatment, and a breakthrough pain treatment to lung cancer…
- Trial name
- NCT01060137
- Testing
- fentanyl matrix
- Volunteers
- 268 people
- Sponsor
- Janssen Korea, Ltd., Korea
Chemotherapy-induced Neutropenia
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced or metastatic breast cancer, who have failed >/= 1 but < 5 prior lines of chemotherapy; locally advanced or metastatic non small cell…
- Trial name
- Protective-1 (NCT03102606)
- Testing
- Plinabulin, Pegfilgrastim
- Where
- 18 sites in United States, China and 2 more
- Volunteers
- 105 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Pain
Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute
As part of the PREA(Pediatric Research Equity Act) commitment, the objective of the study is to confirm safety and tolerability of 25 mg of Zipsor® in clinical pediatric subjects.
- Trial name
- NCT01982539
- Testing
- Zipsor®
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Pain, Breakthrough Cancer Pain
A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain
The primary objective of this study is to evaluate the efficacy of SSR411298 200 mg daily compared to placebo as adjunctive treatment for persistent cancer pain based on Numeric Rating Scale (NRS).
- Trial name
- ACT11705 (NCT01439919)
- Testing
- SSR411298
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sanofi
Opioid-Induced Constipation
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC) in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01901302
- Testing
- CB-5945
- Volunteers
- 61 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pain, Advanced Cancer
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
This 9-week study aimed to determine the efficacy, safety and tolerability of nabiximols (Sativex®) as an adjunctive treatment, compared with placebo in relieving uncontrolled persistent chronic pain in participants with advanced…
- Trial name
- NCT01262651
- Testing
- Nabiximols
- Where
- 72 sites in United States, Belgium and 10 more
- Volunteers
- 397 people
- Sponsor
- GW Pharmaceuticals Ltd
Uterine Fibroids, Endometriosis
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in…
- Trial name
- NCT05862272
- Testing
- Relugolix Combination Tablet
- Where
- 120 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Pain
Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)
Primary: To compare the efficacy of nasal fentanyl (NF) to oral transmucosal fentanyl (Actiq®) (hereafter Actiq) in the management of breakthrough pain in cancer patients.
- Trial name
- NCT00496392
- Testing
- Nasal fentanyl
- Where
- Denmark
- Volunteers
- 115 people
- Sponsor
- Nycomed
Herpes Zoster
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)
This is a randomized, double-blind, placebo-controlled study to assess the safety and tolerability of V212 when administered to adults with solid tumor malignancy (STM) receiving chemotherapy and to assess the impact of V212 on…
- Trial name
- NCT01254630
- Testing
- V212
- Volunteers
- 5,305 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasm Metastasis, Palliative Care
A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone
The purpose of this study is to investigate the safety and efficacy of tanezumab in combination with opioids in treating pain due to cancer that has spread to bone.
- Trial name
- NCT00545129
- Testing
- Tanezumab 10 mg IV
- Where
- 39 sites in United States, Austria and 11 more
- Volunteers
- 59 people
- Sponsor
- Pfizer
Pain, Bone Neoplasm
A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.
This single arm study will assess the efficacy of loading doses of intravenous Bondronat in reducing pain in patients with breast cancer and metastatic bone disease experiencing moderate to severe bone pain.
- Conditions
- Pain, Bone Neoplasm, Neoplasm Metastasis
- Trial name
- NCT00478270
- Testing
- ibandronate [Bondronat]
- Where
- 6 sites in Greece
- Sponsor
- Hoffmann-La Roche
Bone Pain, Metastatic Bone Tumor
Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.
- Conditions
- Bone Pain, Metastatic Bone Tumor, Bone Metastases in Subjects With Advanced Cancer
- Trial name
- SOLACE (NCT07197645)
- Testing
- 153Sm-DOTMP
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Pain, Advanced Cancer
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
This was a six-month open-label extension (OLE) study to evaluate the safety of long-term nabiximols (Sativex®) therapy when used as an adjunctive treatment in participants with advanced cancer.
- Trial name
- NCT01337089
- Testing
- Nabiximols
- Where
- 128 sites in United States, Australia and 16 more
- Volunteers
- 660 people
- Sponsor
- Jazz Pharmaceuticals
Pain
Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer
This study will evaluate the efficacy and safety of 4 mg zoledronic acid administered intravenously every 3-4 weeks in the treatment of bone metastases-related pain in patients with prostate cancer.
- Trial name
- TRAPEZE (NCT00375648)
- Testing
- Zoledronic acid
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Uterine Fibroids
A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
The purpose of this study is to evaluate the efficacy and safety of Relugolix (TAK-385) in patients having pain symptoms associated with uterine fibroids.
- Trial name
- NCT02655224
- Testing
- Relugolix
- Where
- 11 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Takeda